Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology
文献类型：期刊论文
| 作者 | Ji, Shuyi1,2; Feng, Li3; Fu, Zile2; Wu, Gaohua2; Wu, Yingcheng2; Lin, Youpei2; Lu, Dayun4,5; Song, Yuanli4,5; Cui, Peng6; Yang, Zijian2 |
| 刊名 | SCIENCE TRANSLATIONAL MEDICINE
 |
| 出版日期 | 2023-07-26 |
| 卷号 | 15期号:706页码:15 |
| ISSN号 | 1946-6234 |
| DOI | 10.1126/scitranslmed.adg3358 |
| 通讯作者 | Zhou, Hu(gaoqiang@fudan.edu.cn) ; Sun, Yidi(ydsun@ion.ac.cn) ; Gao, Qiang(zhouhu@simm.ac.cn) |
| 英文摘要 | Organoid models have the potential to recapitulate the biological and pharmacotypic features of parental tumors. Nevertheless, integrative pharmaco-proteogenomics analysis for drug response features and biomarker investigation for precision therapy of patients with liver cancer are still lacking. We established a patient-derived liver cancer organoid biobank (LICOB) that comprehensively represents the histological and molecular characteristics of various liver cancer types as determined by multiomics profiling, including genomic, epigenomic, transcriptomic, and proteomic analysis. Proteogenomic profiling of LICOB identified proliferative and metabolic organoid subtypes linked to patient prognosis. High-throughput drug screening revealed distinct response patterns of each subtype that were associated with specific multiomics signatures. Through integrative analyses of LICOB pharmaco-proteogenomics data, we identified the molecular features associated with drug responses and predicted potential drug combinations for personalized patient treatment. The synergistic inhibition effect of mTOR inhibitor temsirolimus and the multitargeted tyrosine kinase inhibitor lenvatinib was validated in organoids and patient-derived xenografts models. We also provide a user-friendly web portal to help serve the biomedical research community. Our study is a rich resource for investigation of liver cancer biology and pharmacological dependencies and may help enable functional precision medicine. |
| WOS关键词 | HEPATOCELLULAR-CARCINOMA ; SENSITIVITY ; ACTIVATION ; PATHWAY ; HGF |
| WOS研究方向 | Cell Biology ; Research & Experimental Medicine |
| 语种 | 英语 |
| 出版者 | AMER ASSOC ADVANCEMENT SCIENCE |
| WOS记录号 | WOS:001037244900001 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/306911]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Zhou, Hu; Sun, Yidi; Gao, Qiang |
| 作者单位 | 1.Fudan Univ, Jinshan Hosp, Ctr Tumor Diag & Therapy, Shanghai 201508, Peoples R China 2.Fudan Univ, Key Lab Carcinogenesis & Canc Invas, Dept Liver Surg & Transplantat, Liver Canc Inst,Zhongshan Hosp,Minist Educ, Shanghai 200032, Peoples R China 3.Chinese Acad Sci, Inst Neurosci, CAS Ctr Excellence Brain Sci & Intelligence Techn, Shanghai 200031, Peoples R China 4.Chinese Acad Sci, Dept Analyt Chem, Shanghai 201203, Peoples R China 5.Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, Shanghai 201203, Peoples R China 6.Burning Rock Biotech, Shanghai 201114, Peoples R China 7.D1 Med Technol, Shanghai 200235, Peoples R China 8.Chinese Acad Sci, Inst Pasteur Shanghai, Key Lab Mol Virol & Immunol, Shanghai 200031, Peoples R China 9.Fudan Univ, Shanghai Canc Ctr, Dept Radiat Oncol, Shanghai 200032, Peoples R China 10.Fudan Univ, Shanghai Canc Ctr, Canc Inst, Shanghai 200032, Peoples R China |
| 推荐引用方式 GB/T 7714 | Ji, Shuyi,Feng, Li,Fu, Zile,et al. Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology[J]. SCIENCE TRANSLATIONAL MEDICINE,2023,15(706):15. |
| APA | Ji, Shuyi.,Feng, Li.,Fu, Zile.,Wu, Gaohua.,Wu, Yingcheng.,...&Gao, Qiang.(2023).Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology.SCIENCE TRANSLATIONAL MEDICINE,15(706),15. |
| MLA | Ji, Shuyi,et al."Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology".SCIENCE TRANSLATIONAL MEDICINE 15.706(2023):15. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。